Djay Adx

Amandeep Singh known by the stage name Djay Adx, (Previously known as Adx) is an Indian Hip-Hop Producer and Rap Artist from New Delhi, India. He is best known for his role in #HipHopIsHipHop which is a Hip Hop version of "We Are The World" charity single. He has been part of Indian mufor more than asic industry decade now. He is a trained DJ by the Midnight Blues Camp. He is also one of the first and foremost Indian DJs to be Certified by music equipment’s brand Pioneer Corporation, Japan. He is a certified Music Production Professional from BeatFactory Academy. Adx specializes in producing Urban Desi Music and is also the owner of India’s first Desi Hip-Hop Crew Nau Sau Bai aka 922; to have a track played on Indian mainstream television channels followed by a full length interview on PTC Punjabi and BBC Asian Network.

Musical career

He started his Musical Journey as a DJ by playing at Private Parties and Clubs and started making Bootleg Recordings in early 2000s despite of family support. After seeing too much competition in DJing field he took his musical passion to the next level by learning Music Production and making Mainstream music.

ADX-47273

ADX-47273 is a research pharmaceutical developed by Addex Therapeutics which acts as a positive allosteric modulator (PAM) selective for the metabotropic glutamate receptor subtype mGluR₅. It has nootropic and antipsychotic effects in animal studies, and has been used as a lead compound to develop improved derivatives.

See Also

References

ADX-71149

ADX-71149, also known as JNJ-4041183 and JNJ-mGluR2-PAM, is a selective positive allosteric modulator of the mGlu₂ receptor. It is being studied by Addex Therapeutics and Janssen Pharmaceuticals for the treatment of schizophrenia. It was also researched by these companies for the treatment of anxious depression (major depressive disorder with anxiety symptoms), but although some efficacy was observed in clinical trials, it was not enough to warrant further development for this indication. As of 2015, ADX-71149 is in phase II clinical trials for schizophrenia.

See also

References

External links